AB Science receives US patent for masitinib to treat sickle cell disease: Paris Friday, December 26, 2025, 14:00 Hrs [IST] AB Science SA, a pharmaceutical company specializing in ...
CAMBRIDGE, Mass., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced new ...
Guideline adherence for opioid pain medications was found to be suboptimal among patients with sickle cell disease pain in the ED.
MedPage Today on MSNOpinion
'I Don't Know How Many Died': What We Heard This Year
In place of our usual "What We Heard This Week" feature, and as part of our year-end wrap-ups, we've selected some of the ...
For those willing to take a chance, let's consider two biotech stocks that could eventually become solid, well-established drugmakers: CRISPR Therapeutics ( CRSP 0.76%) and Viking Therapeutics ( VKTX ...
After a complex development process, Israel’s Ministry of Defense Directorate of Defense R&D (DDR&D) (MAFAT) and Rafael ...
Medical Xpress on MSN
Long-Term Multivitamin Use Lowers Hypertension Risk in Some Older Adults
Discover how taking a daily multivitamin was associated with lowered blood pressure and hypertension risk in older adults ...
AB Science (ABSCF) announced that the United States Patent Office has formally granted a patent for methods of treating sickle cell disease using ...
Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopeniaNovel treatment targets BTK through multi-immune ...
Analysts project the U.S. diabetes market will surge past $75 billion by 2031, driven by advanced cell therapies and continuous glucose monitoring systems transforming patient care [3]. Regenerative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback